[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362432-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362432-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","clinical-and-genetic-insights-into-novel-tp53-mutations-in-de-novo-aml-patients-research","Clinical and genetic insights into novel TP53 mutations in De Novo AML patients - Research","","Study explores potential TP53 variations in exons 3–7, a region linked to abundant oncogenic changes affecting DNA structural stability and p53 functional activity. TP53 exons 3–7 were amplified from 90 de novo AML patients and analyzed via Sanger sequencing for nucleotide variants. Ten coding-region mutations were identified as unique regional alterations, and bioinformatics suggested likely hazardous effects for most variants in the core DNA binding domain. Clinical features (excluding platelet count) and survival outcomes showed no significant differences between TP53 wild type and mutant groups for EFS and OS.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/clinical-and-genetic-insights-into-novel-tp53-mutations-in-de-novo-aml-patients-research/362432/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/clinical-and-genetic-insights-into-novel-tp53-mutations-in-de-novo-aml-patients-research/362432.png","ImageObject",300,407,{"name":42,"@type":43},"Jacob","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which TP53 region was investigated in this study, and why?","Question",{"text":63,"@type":64},"The study focused on TP53 exons 3–7 because this region is reported to harbor abundant oncogenic variations that can adversely affect structural stability and functional activity.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were TP53 mutations identified in the de novo AML patients?",{"text":68,"@type":64},"TP53 exons 3–7 were amplified from 90 de novo AML patients, and the resulting amplicons were Sanger sequenced to detect nucleotide variations.",{"name":70,"@type":61,"acceptedAnswer":71},"Did TP53 mutations affect clinical features or survival outcomes?",{"text":72,"@type":64},"Clinical features did not differ significantly between TP53 wild type and mutant groups except for platelet count. Event-free survival and overall survival also showed no statistically considerable differences between groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362432,1790536179,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},962084931830,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","Clinical and Experimental Medicine (2026) 26:149  \n[https://doi.org/10.1007/s10238-026-02079-6](https://doi.org/10.1007/s10238-026-02079-6)  \nRESEARCH  \nClinical and genetic insights into novel TP53 mutations in De Novo AML patients  \nAfia Muhammad Akram1 · Sikandar Hayat2 · Hassan Yousaf3 · Noreen Sarwar4 · Asma Tahir1 · Sakina Ali1 · Fatima Yaqoob1 · Amjad Zafar5 · Hesham M. Hassan6 · Mutwakel Dabiellil7 · Malik Ihsan Ullah Khan2  \nReceived: 3 October 2025 / Accepted: 26 January 2026 © The Author(s) 2026  \nAbstract  \nThis study intended to uncover any potential variations in TP53 gene particularly the exons 3–7 as this region is reported to have abundant oncogenic variations with adverse impacts on its structural stability and functional activities. The selected region of TP53 was amplified in ninety de novo AML patients and amplicons were Sanger sequenced to analyze possible nucleotide variations. Ten (10) mutations were found in the coding region of the TP53 exons 3–7 which are unique to the regional mutation data in AML patients. Further evaluation of identified variants by employing multiple bioinformatics techniques revealed likely hazardous impacts of majority of them due to their existence in the core DNA binding domain. Clinical features with the exception of platelet count did not differ significantly among the AML patients within TP53 wild type and TP53 mutant groups. Concurrently, no statistically considerable difference was observed in event free survival (EFS) (p = 0.67, HR = 1.222) or overall survival (OS) (p = 0.74, HR = 0.837) comparing two groups.  \nKeywords TP53 · Genetic variations · Acute myeloid leukemia · Cell cycle · In Silico analysis  \nIntroduction  \nAcute Myeloid Leukemia is a genetically heterogeneous clonal disorder that influences the normal mechanism of selfrenewal, proliferation, and differentiation in hematopoietic  \n􀀍 Afia Muhammad Akram[afiamakram@ue.edu.pk](afiamakram@ue.edu.pk)  \n􀀍 Malik Ihsan Ullah Khan [ihsan.ullah@imbb.uol.edu.pk](ihsan.ullah@imbb.uol.edu.pk)  \n1 Department of Zoology, Division of Science and Technology, University of Education, Lahore, Pakistan  \n2 Institute of Molecular Biology and Biotechnology, The University of Lahore, Lahore, Pakistan  \n3 Department of Chemistry and Biotechnology, Swinburne University of Technology, Melbourne 3122, Australia  \n4 Department of parasitology, University of veterinary and animal Sciences, Lahore, Pakistan  \n5 Department of Oncology, Jinnah Hospital, Lahore, Pakistan  \n6 Department of pathology, college of Medicine, King Khalid University, Abha, Saudi Arabia  \n7 Upper Nile University, PO Box 1660, Wau, Malakal Khartoum, South Sudan  \nprogenitor cells [1] . Although AML can affect individuals of any age, it primarily affects those over 60 [2] . As per the 2025 statistics summarized from SEER and American Cancer Society, it was projected that 22,010 new cases ofAMLare expected to be recorded in the United States, with an estimated 11,090 deaths [3] .  \nMultiple genetic variations are thought to impact the development of AML. In addition to many fusion oncogenes, TP53 also serves as the most important gene in cell division, regulating every aspect including the start of cell cycle and cell death. Encoding the p53 protein on chromosome 17 with 11 exons, it functions as a transcription factor. In patients with de novo AML, TP53 variations contribute around 10%, 20–37% in t-AML/s-AML, and around 70% variations found in patients with complex karyotype [4] . It has five signature domains: N-terminal transactivation, proline-rich, DNA-binding, oligomerization, and C-terminus regulation. In cancerous cells, most variations are found in the DNA-binding domain of the TP53 gene [5] . TP53 is oneof the most investigated genes in myeloid malignancies. In AML cases, the TP53 mutational burden has also emerged as a critical prognostic marker and therapy decision factor [6] . It acts as the “guardian of the human genome” and encodes for the transcriptio","cbCaivz6xipkqX7X","https://ap.wps.com/l/cbCaivz6xipkqX7X","pdf",1761764,"English","# Abstract\n# Introduction\n# Materials and methods\n## Blood sample collection\n## Clinical parameters of AML patients","[{\"question\":\"Which TP53 region was investigated in this study, and why?\",\"answer\":\"The study focused on TP53 exons 3–7 because this region is reported to harbor abundant oncogenic variations that can adversely affect structural stability and functional activity.\"},{\"question\":\"How were TP53 mutations identified in the de novo AML patients?\",\"answer\":\"TP53 exons 3–7 were amplified from 90 de novo AML patients, and the resulting amplicons were Sanger sequenced to detect nucleotide variations.\"},{\"question\":\"Did TP53 mutations affect clinical features or survival outcomes?\",\"answer\":\"Clinical features did not differ significantly between TP53 wild type and mutant groups except for platelet count. Event-free survival and overall survival also showed no statistically considerable differences between groups.\"}]","Clinical and genetic insights into novel TP53 mutations in De Novo AML patients - Research | PDF",1790147698,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ad15897092fe57d820683e4535512c8f.webp",983,1305,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e4e467ac01a7ba415f5c265f428df3e1.webp",982,1304,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c69ece0b69fcac49f5afa063d38b2302.webp",981,1303,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7264c80c35dfe61537b7c75b81c01c77.webp",980,1301]